logo

More info
  • ReceivedMar 3, 2020
  • AcceptedMar 23, 2020
  • PublishedMar 25, 2020

Abstract

There is no abstract available for this article.


Funded by

the grants from Sichuan Science and Technology Program(2020YFS0014,2020YFS0558)

the Chinese Academy of Medical Sciences(2019-I2M-5-032)

Technology & Science & Technology Bureau of Chengdu(2020-YF05-00060-SN,2020-YF05-00075-SN)


Acknowledgment

We thank all the participants and their families for participating in this study. This work was supported by the grants from Sichuan Science and Technology Program (2020YFS0014 and 2020YFS0558), the Chinese Academy of Medical Sciences (2019-I2M-5-032) and Technology & Science & Technology Bureau of Chengdu (2020-YF05-00060-SN and 2020-YF05-00075-SN).


Interest statement

The author(s) declare that they have no conflict of interest. This study was performed in accordance with the principles of the Helsinki Declaration of the World Medical Association. The protocol was approved by the Institutional Ethics Committee of the Sichuan Provincial People’s Hospital.


Supplement

SUPPORTING INFORMATION

Figure S1 SDS-PAGE analysis and Western blot of the N protein, the RBD of the S protein, and the binding curve of the RBD-mFc to human ACE2.

Table S1 Demography and clinical classification of COVID-19 patients

The supporting information is available online at http://life.scichina.com and https://link.springer.com. The supporting materials are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains entirely with the authors.


References

[1] Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce H., Spitters C., Ericson K., Wilkerson S., Tural A., et al. First case of 2019 novel coronavirus in the United States. N Engl J Med, 2020, 382: 929-936 CrossRef PubMed Google Scholar

[2] Leung D.T.M., Tam F.C.H., Ma C.H., Chan P.K.S., Cheung J.L.K., Niu H., Tam J.S.L., Lim P.L.. Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J INFECT DIS, 2004, 190: 379-386 CrossRef PubMed Google Scholar

[3] Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 2020, 395: 565-574 CrossRef Google Scholar

[4] Negida, A., Fahim, N.K., and Negida, Y. (2019). Sample size calculation guide-part 4: how to calculate the sample size for a diagnostic test accuracy study based on sensitivity, specificity, and the area under the ROC curve. Adv J Emerg Med 3, e33. Google Scholar

[5] Woo P.C.Y., Lau S.K.P., Wong B.H.L., Tsoi H.W., Fung A.M.Y., Kao R.Y.T., Chan K.H., Peiris J.S.M., Yuen K.Y.. Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia. J Clin MicroBiol, 2005, : 3054-3058 CrossRef PubMed Google Scholar

[6] Xiao S.Y., Wu Y., Liu H.. Evolving status of the 2019 novel coronavirus infection: proposal of conventional serologic assays for disease diagnosis and infection monitoring. J Med Virol, 2020, 92: 464-467 CrossRef PubMed Google Scholar

[7] Yang, Y., Shen, C., Wang, F., Yuan, J., Li, J., Zhang, M., Wang, Z., Xing, L., Wei, J., Peng, L., et al. (2020). Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. BioRxiv, doi: 10.1101/2020.02.11.20021493. Google Scholar

[8] Yuan Y., Cao D., Zhang Y., Ma J., Qi J., Wang Q., Lu G., Wu Y., Yan J., Shi Y., et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat Commun, 2017, 8: 15092 CrossRef PubMed Google Scholar

  • Figure 1

    (Color online) Results and ROC curve of antibodies for SARS-CoV-2 detected by ELISA and chemiluminescence. A, A450 values of the two groups (positive and negative controls) tested by rN-based IgG. B, A450 values analyzed by rS-based IgG in different groups. C, A450 values in two groups from rN-based IgM testing. D, For rS-based IgM analysis, different groups showed differing A450 values. E, For IgG analysis in chemiluminescence, different groups showed differing values. F, For IgM analysis in chemiluminescence, different groups showed differing values. G, ROC curve for rN-based IgG. H, ROC curve analyzed by rS-based IgG. I, ROC curve from rN-based IgM testing. J, ROC curve for rS-based IgM analysis. K, The ROC curve for IgG testing in chemiluminescence. L, The ROC curve analyzed by IgM testing in chemiluminescence. ***, P<0.0001.

Copyright 2020  CHINA SCIENCE PUBLISHING & MEDIA LTD.  中国科技出版传媒股份有限公司  版权所有

京ICP备14028887号-23       京公网安备11010102003388号